Management of atrial fibrillation in patients taking targeted cancer therapies

Cardio-Oncology
Aarti AsnaniLeon M Ptaszek

Abstract

Atrial fibrillation (AF) is frequently observed in patients being treated for cancer and can lead to increased morbidity and mortality in this population. With the use of newer, targeted cancer therapies, several drug-drug interactions have emerged that complicate the use of antiarrhythmic drugs (AADs) in patients with active malignancy. Moreover, specific targeted therapies such as ibrutinib may contribute directly to the development of AF. The decision to pursue systemic anticoagulation can be challenging in patients with malignancy due to a number of factors, including the need for frequent procedures, the presence of malignancy-related risk factors for bleeding, and limited data regarding the safety of the novel oral anticoagulants (NOACs) in cancer patients. This review describes the challenges associated with AF management in patients with cancer and highlights a number of important drug-drug interactions that can impact patient management.

References

Jul 11, 2003·The New England Journal of Medicine·Agnes Y Y LeeUNKNOWN Randomized Comparison of Low-Molecular-Weight Heparin versus Oral Anticoagulant Therapy for the Prevention of Recurrent Veno
May 4, 2007·Journal of General Internal Medicine·Adam J RoseElaine M Hylek
Sep 9, 2008·Journal of Medical Case Reports·Ulas Darda BayraktarOfem Ibiah Ajah
Sep 1, 2009·The New England Journal of Medicine·Stuart J ConnollyUNKNOWN RE-LY Steering Committee and Investigators
Oct 6, 2009·Europace : European Pacing, Arrhythmias, and Cardiac Electrophysiology : Journal of the Working Groups on Cardiac Pacing, Arrhythmias, and Cardiac Cellular Electrophysiology of the European Society of Cardiology·Maya GuglinAnne B Curtis
Mar 31, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Toni K ChoueiriJoaquim Bellmunt
Nov 13, 2010·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Lifei WangDonglu Zhang
Apr 26, 2011·The Journal of Pharmacology and Experimental Therapeutics·Mark Jean GnothSteffen Sandmann
Aug 13, 2011·The New England Journal of Medicine·Manesh R PatelUNKNOWN ROCKET AF Investigators
Aug 30, 2011·The New England Journal of Medicine·Christopher B GrangerUNKNOWN ARISTOTLE Committees and Investigators
Sep 20, 2012·International Journal of Cardiology·Yu-feng HuShih-ann Chen
Oct 10, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Ranjana H AdvaniNathan H Fowler
Dec 18, 2012·European Journal of Cardio-thoracic Surgery : Official Journal of the European Association for Cardio-thoracic Surgery·Takashi NojiriMeinoshin Okumura
Feb 6, 2013·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Donglu ZhangW Griffith Humphreys
Apr 9, 2013·Journal of the American College of Cardiology·Jeffrey D WesslerRobert P Giugliano
Nov 21, 2013·The New England Journal of Medicine·Robert P GiuglianoUNKNOWN ENGAGE AF-TIMI 48 Investigators
Jun 3, 2014·The New England Journal of Medicine·John C ByrdUNKNOWN RESONATE Investigators
Jun 4, 2014·CA: a Cancer Journal for Clinicians·Carol E DeSantisAhmedin Jemal
Aug 15, 2014·PloS One·Eva B OstenfeldHenrik T Sørensen
Nov 6, 2015·International Journal of Cardiology·Yong-Joon LeeBoyoung Joung
Dec 8, 2015·The New England Journal of Medicine·John C ByrdRichard R Furman
Jul 22, 2016·JAMA Cardiology·Faisal RahmanEmelia J Benjamin
Jul 22, 2016·JAMA Cardiology·David ConenChristine M Albert
Oct 28, 2016·British Journal of Haematology·Philip A ThompsonFlorence Cymbalista

❮ Previous
Next ❯

Citations

Jul 18, 2018·Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners·Chris J KapeliosNora-Athina Viniou
May 16, 2020·Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer·Suheil Albert Atallah-YunesSyed S Ali
Mar 1, 2021·Heart Rhythm : the Official Journal of the Heart Rhythm Society·Charlotte LeeMichael G Fradley

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antiarrhythmic Agents: Mechanisms of Action

Understanding the mechanism of action of antiarrhythmic agents is essential in developing new medications as treatment of cardiac arrhythmias is currently limited by the reduced availability of safe and effective drugs. Discover the latest research on Antiarrhythmic Agents: Mechanism of Action here.

Atrial Fibrillation

Atrial fibrillation is a common arrhythmia that is associated with substantial morbidity and mortality, particularly due to stroke and thromboembolism. Here is the latest research.

Atrial Filbrillation

Atrial fibrillation refers to the abnormal heart rhythm characterized by rapid and irregular beating of the atria. Here is the latest research.

Arrhythmia

Arrhythmias are abnormalities in heart rhythms, which can be either too fast or too slow. They can result from abnormalities of the initiation of an impulse or impulse conduction or a combination of both. Here is the latest research on arrhythmias.

Anti-Arrhythmic Drug Therapies

Anti-arrhythmic drugs are used to prevent abnormal heart rhythms. These medications are used in conditions including, ventricular tachycardia, ventricular fibrillation and atrial fibrillation. Discover the latest research on anti-arrhythmic drug therapies here.

Related Papers

Journal of Atrial Fibrillation
Francesco VioliPasquale Pignatelli
Avicenna Journal of Medicine
Anish AminMahmoud Houmsse
Europace : European Pacing, Arrhythmias, and Cardiac Electrophysiology : Journal of the Working Groups on Cardiac Pacing, Arrhythmias, and Cardiac Cellular Electrophysiology of the European Society of Cardiology
Mohammad ShenasaFatemah Shenasa
© 2021 Meta ULC. All rights reserved